Oncology Letters Special Issues

Extracellular vesicles in three-dimensional cancer models

Lead Editor:

    Dr ILARIA GIUSTI
    University of L'Aquila
    Italy

Extracellular vesicles (EVs) are lipid-bilayer enclosed vesicles released from almost all cells as means of cell-to-cell communication, in both physiological and pathological processes. The role of EVs has been widely studied in cancer diseases, mostly using the classical monolayer culture models. It is well documented, instead, that 2D (monolayer) or 3D (including spheroids, organoids, or scaffolds) culture conditions differ in terms of cell-cell interaction, morphology, proliferation, and signal transduction; although the 2D model is still the most widely used in vitro, 3D culture appears to be more suitable for mimicking tissue architecture and cell behavior in vivo. Only few information on EVs biology have been obtained from 3D models; however, being the plasma membrane widely involved in the release of EVs, it is possible that the type of cell-cell interaction in a 2D or 3D model could deeply affect their characteristics in terms of number, size, and molecular cargo. The special issue could collect studies conducted on three-dimensional culture models, included in the following, not exhaustive, list: - Tissues - Spheroids - Organoids - Neurospheres - Mammospheres - Scaffolds - Organ-on-chip


Submission deadline: 07 February 2023

COVID-19 infection and cancer - multiple impact areas

Lead Editor:

    Dr Constantin Caruntu
    "Carol Davila" University of Medicine and Pharmacy
    Romania

The COVID-19 pandemic is considered a global health threat of unprecedented magnitude in our times. Through infectious mechanisms, massive inflammation, impaired coagulation pathways, destructive processes with abnormal regeneration that take place at systemic level, it induces an increased risk in patients with chronic diseases. Cancer patients in particular have a higher risk of morbidity and mortality associated with COVID-19 infection. On the one hand, the underlying malignancy causes a weakening of these patients, and the associated treatment can have a major impact on the functioning of the immune response. On the other hand, the important inflammatory phenomena, the impaired defense system and other cellular and molecular mechanisms associated with the infection could contribute to the increased risk of cancer development and progression. Moreover, the COVID-19 pandemic affects the health care systems, generating a major overload. This delays the diagnosis, treatment and follow-up of cancer patients. It also affects the proper development of cancer screening and prevention programs. Understanding the impact on health systems allows them to adapt quickly to the challenges associated with the COVID-19 pandemic, by reorganizing and modifying work strategies, redesigning diagnosis, therapeutic and follow-up protocols, implementing modern techniques such as telemedicine, digital health and artificial intelligence technology. Also, the COVID-19 pandemic could alter the paradigms of cancer research and could have a long-term impact in cancer care. This Special Issue aims to bring together articles on these various possible areas of impact between COVID-19 infection and cancer.


Submission deadline: 21 January 2023

Non-coding RNA at the Frontier of Early Diagnosis, Prognosis Evaluation, and Cancer Treatments

Lead Editor:

    Dr Ying Liu
    Institute for Translational Medicine, Qingdao University
    China

Non-coding RNAs (ncRNAs), such as lncRNAs, circRNAs, miRNAs, are involved in practically all aspects of cancer progression. These ncRNAs show significant differential expression pattern in both biofluids and tissue samples of patients. The biofluids can be easily and reproducibly collected for analyses. The rapid advances in high-throughput sequencing technologies and bioinformatics have further helped the development of ncRNA-based therapeutic strategy and diagnostic tests used by clinicians. This special issue focuses on the clinical aspects of ncRNAs, in particular validation of novel biomarkers that may serve as signature for non-invasive early detection of cancerous cells, predict patients' prognosis and response to specific therapies.


Submission deadline: 07 January 2023

Management of prostate cancer in 2022

Lead Editor:

    Dr Carole Hélissey
    Department of medical oncology HIA Bégin
    France

From emerging new hormonotherapy, PARP inhibitors, to metabolic therapy. The development of these treatments initially in monotherapy and later in combination therapy has clearly improved the survival of patients at first in the metastatic stage and today in the localized stage. However, which treatment for each patient? When to introduce it? How to monitor the effectiveness, beyond the PSA, which imaging? Theranostic should now be developed for patients with prostate cancer. More than 85% of patients will be alive 5 years after their diagnosis, all stages combined, so the quality of life of these patients is important. In this Special Issue, we invite research that highlights further advances in prostate cancer diagnostic, therapies, patient care.


Submission deadline: 29 December 2022

Molecular target and action mechanism of anti-cancer agents

Lead Editor:

    Professor Seok-Geun Lee
    Kyung Hee University
    Republic of Korea

Recent advances in genomics, proteomics, and metabolomics are changing the way physicians and scientists approach the diagnosis and treatment of cancer. Increased knowledge of cancer diagnosis with more detailed stratification based on patient omics data helps to move the field of precision oncology forward. In addition, developing new anti-cancer drugs targeting genetic changes is another important part of precision oncology. In this context, this Special Issue aims to cover molecular-mechanism-based research for anticancer therapy. It welcomes original research, and review articles on the discovery of molecular targets or/and molecular mechanisms of any anti-cancer agents, including conventional chemotherapy, novel potential anti-cancer drug candidates, and their combinations with any other anti-cancer modalities.


Submission deadline: 28 December 2022

The management of brain metastasis: recent treatment and future directions

Lead Editor:

    Dr Atsuto Katano
    University of Tokyo Hospital
    Japan

Brain metastasis causes neurological symptoms depending on the localization of the lesion and the degree of surrounding edema and might be a detriment to the quality of life of the patients. Even if the patient is asymptomatic, neurological symptoms may appear in a short period of time. Although brain metastasis occurs of patients with advanced-stage cancer, the prognosis of cancer patients has been improved in recent years due to advances in systemic therapy, especially molecular targeted agents and immune checkpoint inhibitors. On the other hand, the frequency of asymptomatic brain metastasis is gradually increasing due to the development of diagnostic imaging such as magnetic resonance imaging, and the management of brain metastasis has become one of the most important issues in cancer treatment in order to proceed with treatment without decreasing the quality of life of patients as much as possible. This review focused on the appropriate management of brain metastasis in cancer treatment.


Submission deadline: 22 December 2022

Role of Wnt signaling pathway in lung cancer

Lead Editor:

    Dr Noriaki Sunaga
    Gunma University Graduate School of Medicine
    Japan

The Wnt signaling pathway is classified into β-catenin-dependent (canonical) and -independent (non-canonical) pathways, both of which play pivotal roles in embryonic development and the regulation of many cellular functions. A close link between cancer and the canonical Wnt/β-catenin pathway has long been studied and growing evidence indicates that constitutive activation of the Wnt signaling by altered component of its pathway implicates in tumor growth, metastasis, angiogenesis, chromosome instability, cancer stemness, epithelial to mesenchymal transformation and immunomodulation of tumor microenvironment. Moreover, the Wnt pathway affects acquisition of resistance to molecular targeted drugs and immune checkpoint inhibitors. This special issue focuses on the role of Wnt signaling pathway in the tumorigenesis and therapeutic resistance in lung cancer.


Submission deadline: 22 December 2022

Journal Cover

November-2022
Volume 24 Issue 5

Print ISSN: 1792-1074
Online ISSN: 1792-1082

Sign up for eToc alerts

Recommend to Library

Full Size Image